PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect

As mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumour tissues by circumventing all the shortcomings of conventional chemotherapy

Sarbari Acharya

2010

Scholarcy highlights

  • As mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumour tissues by circumventing all the shortcomings of conventional chemotherapy
  • Poly(lactic-co-glycolic acid) is a widely used polymer for fabricating ‘nanoparticles’ because of biocompatibility, long-standing track record in biomedical applications and well-documented utility for sustained drug release, and has been the centre of focus for developing drug-loaded nanoparticles for cancer therapy. Such poly(lactic-co-glycolic acid) nanoparticles have been used to develop proteins and peptides for nanomedicine, and nanovaccines, as well as a nanoparticle-based drug- and gene-delivery system for cancer therapy, and nanoantigens and growth factors. These drug-loaded nanoparticles extravasate through the tumour vasculature, delivering their payload into the cells by the enhanced permeability and retention effect, thereby increasing their therapeutic effect
  • Ongoing research about drug-loaded nanoparticles and their delivery by the EPR effect to the tumour tissues has been elucidated in this review with clarity
  • This review is part of the Advanced Drug Delivery Reviews theme issue on "enhanced permeability and retention effect based drug design and clinical outlook for enhanced cancer chemotherapy"

Need more features? Save interactive summary cards to your Scholarcy Library.